Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2014

View Archived Issues

Phase I/II results for cell therapy-based replacement of retinal pigment epithelium

Oasmia's Paclical demonstrates positive risk/benefit profile in comparison with Taxol

Clinical response maintained with long-term brodalumab therapy in patients with psoriasis

PNPLA3 gene polymorphism associated with gallbladder cholesterol polyps

Critical Outcome Technologies and MD Anderson Cancer Center to evaluate COTI-2

SomaLogic and Novartis extend proteomics agreement

Addex and the Charcot-Marie-Tooth Association to advance ADX-71441

Asterias Biotherapeutics provides update on grant award from CIRM for AST-OPC1 trial

Phase II HIV treatment ibalizumab receives U.S. orphan drug designation

FDA grants tipelukast orphan drug status for IPF

Athera begins phase I trial of fully human antibody PC-mAb

Early clinical data for maternal immunization with the trivalent GBS vaccine

Aurigene Discovery Technologies discloses new TAK1 inhibitors

Novel anti-staphylococcal enterotoxin B MAbs divulged

In vivo testing of novel GPR-directed [99mTc]demobesin mimics

KU Leuven discloses new viral replication inhibitors for Flaviviridae infections

CHDI Foundation discloses novel HDAC4 inhibitors for Huntington's disease

Bristol-Myers Squibb reports new FFAR4 modulators

Omeros provides update on OMS-824 program

Repros Therapeutics reports results from long-term safety study of Androxal

Companies update development strategies in face of Ebola

GMI-1051 improves efficacy of antibiotic treatments in models of Pseudomonas infection

Relypsa submits NDA to FDA seeking approval of patiromer for hyperkalemia

EMA outlines recent efforts to expedite development of Ebola treatments

Phase III trials of secukinumab in ankylosing spondylitis meet primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...